Zimmer Biomet Holdings Inc. (ZBH) Stock Price Quote, News…

Summary

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Website

www.zimmerbiomet.com

Location

Warsaw, IN, US

Phone574 267 6131

Employees17,000

CEOIvan Tornos

Sector

Materials

Industry

Paper & Forest Products

IPO DateJul 25, 2001

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

Latest Documents

Mentions in Filings

… s that, in accordance with our internal policies regarding the approval of related-party transactions, were approved by our then three Board members that are not affiliated with Air T, Inc. On October 7, 2025, Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”) announced that it had completed its acquisition of Monogram and soon after the announcement we received $4.04 per share in cash for each of the 2,212,378 common shares we owned of Monogram pri …
PRO DEX INCZimmer Biomet Holdings Inc.·ARS - Annual report to security holders·FY26·6 Oct
… rved as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc. (“Lantheus”), a public radiopharmaceutical company, since September 2018. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), a public global medical device company with a leading position in musculoskeletal health, in which he held various senior leadership roles, including Vice President, Investor Relations and Co …
Lifeward Ltd.Zimmer Biomet Holdings Inc.·ARS - Annual report to security holders·FY26·25 Sep
… s that, in accordance with our internal policies regarding the approval of related-party transactions, were approved by our then three Board members that are not affiliated with Air T, Inc. On October 7, 2025, Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”) announced that it had completed its acquisition of Monogram and soon after the announcement we received $4.04 per share in cash for each of the 2,212,378 common shares we owned of Monogram pri …
PRO DEX INCZimmer Biomet Holdings Inc.·10-K - ANNUAL REPORT FY 2026·FY26·3 Sep
… 20% | | 17 | | 178.83 | | 3,040 | | VEEV | Veeva Systems Inc. (Class A) \* | | 0.50% | | 26 | | 295.85 | | 7,692 | | VRTX | Vertex Pharmaceuticals Incorporated \* | | 0.49% | | 15 | | 507.00 | | 7,605 | | ZBH | Zimmer Biomet Holdings, Inc. | | 0.20% | | 34 | | 92.17 | | 3,134 | | Industrials (6.69%): | | | | | | | | | | | AME | AMETEK, Inc. | | 0.50% | | 31 | | 249.89 | | 7,747 | | ADP | Automatic Data Processing, Inc. | | 0.50% | | 28 | | 273.81 …
FT 13273Zimmer Biomet Holdings Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct
… 13% | | 12 | | 178.83 | | 2,146 | | VEEV | Veeva Systems Inc. (Class A) \* | | 0.34% | | 19 | | 295.85 | | 5,621 | | VRTX | Vertex Pharmaceuticals Incorporated \* | | 0.33% | | 11 | | 507.00 | | 5,577 | | ZBH | Zimmer Biomet Holdings, Inc. | | 0.13% | | 24 | | 92.17 | | 2,212 | | Industrials (4.48%): | | | | | | | | | | | AME | AMETEK, Inc. | | 0.33% | | 22 | | 249.89 | | 5,498 | | ADP | Automatic Data Processing, Inc. | | 0.33% | | 20 | | 273.81 …
FT 13272Zimmer Biomet Holdings Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct
… % | | 34 | | 175.72 | | 5,974 | | VEEV | Veeva Systems Inc. (Class A) \* | | 0.83% | | 52 | | 284.84 | | 14,812 | | VRTX | Vertex Pharmaceuticals Incorporated \* | | 0.84% | | 30 | | 503.25 | | 15,097 | | ZBH | Zimmer Biomet Holdings, Inc. | | 0.33% | | 67 | | 88.88 | | 5,955 | | Industrials (11.17%): | | | | | | | | | | | AME | AMETEK, Inc. | | 0.83% | | 60 | | 247.52 | | 14,851 | | ADP | Automatic Data Processing, Inc. | | 0.83% | | 55 | | 270. …
FT 13251Zimmer Biomet Holdings Inc.·487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·9 Oct

Key Stats

Trading

Px/Chg 1D$88.29 / +0.26%

Avg Volume2.22M

Beta0.17

Mkt Cap17.08B

FD Mkt Cap19.30B

Float

Shrs Out/Float193.46M / 193.11M

Short Float0.06%

Days to Cover4.63

Stock Repurchased$250.10M

Current Valuation

EV24.14B

EV/EBITDA10.94

EV/Sales2.87

P/B1.35

P/S2.03

FCF Yield1.89%

ROE1.88%

ROA1.05%

Current Ratio1.73

Dividend

Cash$0.24

Yield116.60%

Yield (TTM)116.60%

Estimates

P/E22.44

Est P/EN/A

Est EPSN/A

Est PEGN/A

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	Apr '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	72.28	125.75	24.37	23.01	116.52	71.74
Price / Sales	5.14	4.19	3.37	2.71	7.24	8.19
Price / Book Value	1.74	2.42	2.00	1.67	1.28	1.35
Price / Free Cash Flow	28.74	27.27	21.02	18.20	24.31	52.90
ENTERPRISE VALUE METRICS
Enterprise Value	27,709.0	34,426.3	30,312.0	26,480.6	23,190.5	24,135.8
Enterprise Value / Sales	6.88	4.96	4.10	3.45	10.34	11.57
Enterprise Value / EBITDA	28.88	23.03	13.65	11.76	51.09	44.84
Enterprise Value / EBIT	61.25	60.58	23.90	21.11	136.49	64.16

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	4.8%	6,827.3	6,939.9	7,394.2	7,678.6	8,231.5
Gross Income	1%	4,866.9	4,920.4	5,310.4	5,487.4	5,071.9
EBITDA	7.7%	1,645.1	1,494.7	2,220.2	2,250.9	2,217.4
EBIT	12.3%	707.4	568.3	1,268.5	1,254.6	1,123.6
Net Income	15.1%	401.6	231.4	1,024.0	903.8	705.2
EPS (Diluted)	16.8%	1.91	1.10	4.88	4.43	3.55
BALANCE SHEET
Cash & ST Inv	11.9%	378.1	375.7	415.8	525.5	591.9
Total Assets	-39.1%	23,456.4	21,066.0	21,496.9	21,365.3	23,091.7
Total Liabilities	-95%	10,790.0	9,039.0	9,008.8	8,889.1	10,385.9
Total Shareholder Equity	7.3%	12,660.7	12,020.3	12,480.5	12,468.1	12,697.7
CASH FLOW
Net Operating Cash Flow	3.1%	1,499.2	1,284.7	1,581.6	1,499.4	1,697.0
Cap Ex	10.2%	-152.0	-217.6	-394.5	-356.8	-224.5
Free Cash Flow	2.2%	1,347.2	1,067.1	1,187.1	1,142.6	1,472.5

Enterprise Value Bridge

Millions USD		23 Oct '26
Price (As of 23 Oct '26)		98.56
Basic Shares		193.46
Market Cap		19,067.6
Diluted Shares		195.80
Fully Diluted Shares Outstanding		195.80
Fully Diluted Market Cap		19,298.0
+Consolidated Debt		7,471.0
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-424.2
−Short-term Investments		-
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		8.2
+Pension Liabilities		—
Enterprise Value		26,122.6

Segment data

Revenue

by Products and services

Knees44%
S E T28%
Hips28%

Revenue

by Geography

Americas62%
E M E A22%
Asia Pacific15%

Zimmer Biomet Holdings Inc.(ZBH US)

Zimmer Biomet Holdings Inc.(ZBH US)

Financials & Metrics